Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 3.4.14.5 extracted from

  • Ahren, B.
    Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin (2008), Vasc. Health Risk Manag., 4, 383-394.
    View publication on PubMedView publication on EuropePMC

Application

Application Comment Organism
medicine DPP-4 inhibition in combination with metformin is an efficient, safe and tolerable combination therapy for type 2 diabetes Homo sapiens

Inhibitors

Inhibitors Comment Organism Structure
NVP-DPP728
-
Homo sapiens
saxagliptin
-
Homo sapiens
sitagliptin MK-0431, trade name Januvia, 100 mg sitagliptin inhibits plasma DPP-4 activity for more than 16 hours after a single administration Homo sapiens
vildagliptin LAF237, trade name Galvus, 100 mg vildagliptin inhibits plasma DPP-4 activity for more than 16 hours after a single administration Homo sapiens

Natural Substrates/ Products (Substrates)

Natural Substrates Organism Comment (Nat. Sub.) Natural Products Comment (Nat. Pro.) Rev. Reac.
glucagon-like peptide 1 + H2O Homo sapiens
-
?
-
?

Organism

Organism UniProt Comment Textmining
Homo sapiens
-
-
-

Substrates and Products (Substrate)

Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
glucagon-like peptide 1 + H2O
-
Homo sapiens ?
-
?

Synonyms

Synonyms Comment Organism
dipeptidyl peptidase-4
-
Homo sapiens
DPP-4
-
Homo sapiens